Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion

Kathryn (Katie) Woods, C. Camacho-Hübner, R. N. Bergman, D. Barter, A. J L Clark, M. O. Savage

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature. Recombinant human IGF-I (rhIGF-I) therapy has been shown to improve insulin sensitivity (Si) and growth in other causes of IGF-I deficiency. We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient, rhIGF-I therapy was initiated at age 16.07 yr (bone age, 14.2 yr), at a starting dose of 40 μg/kg daily, increasing after 3 months to 80 μg/kg daily. Body composition, BMD, markers of bone mineralization, and auxological parameters (height, weight) were measured at 0, 6, and 12 months after start of therapy. Si, acute insulin response to glucose, and glucose effectiveness were determined at baseline, 3 months, and 12 months into therapy. On IGF-I therapy, body mass index increased from 17 kg/m2 to 18.6 kg/m2. Body composition studies (dual-energy x-ray absorbtiometry) revealed an initial decrease in total body fat, from 19.9% at baseline to 15.1% at 6 months; but by 12 months of therapy, this had reversed, with an increase to 21.8%. Si, calculated using Bergman's minimal model, was substantially reduced at baseline at 1.45 × 10-4 min-1 (μU/mL) [normal value, 5.1 × 10-4 min-1 (lean adult male)], rhIGF-I therapy resulted in a dose related improvement of Si into the normal range (NR) (rhIGF-I dose: 40 μg/kg·day, Si = 2.06 × 10-4 min-1; rhIGF-I dose: 80 μg/kg·day, Si = 4.39 × 10-4 min-1). Baseline reduction in Si was accompanied by elevated acute insulin response to glucose, which also fell in a dose-dependent manner. Baseline BMD was severely reduced when compared with age-matched controls (-4.88 SD); however, calculation of bone mineral apparent density indicated that the true reduction in BMD was minimal, rhIGF-I therapy increased BMD by 17% and bone mineral apparent density by 7%, indicating that IGF-I has a greater effect on bone growth than bone mineralization. Bone turnover markers also increased on rhIGF-I; mean serum osteocalcin: 8.3 ng/mL pretreatment, 21.7 ng/mL after 6 months of rhIGF-I (NR for adult male, 3.4-9.1 ng/mL); mean bone specific alkaline phosphatase: 36.5 U/L pretreatment, 82.2 U/L after 6 months of therapy (NR for adult male, 15-41). Height velocity increased from 3.8 cm/yr pretreatment to 7.3 cm/yr on 80 μg/kg·day of rhIGF-I. In this patient with severe insulin resistance, therapy with rhIGF-I resulted in beneficial effects on Si, body composition, bone size, and linear growth. These results have implications for IGF-I therapy in a variety insulin resistant states.

Original languageEnglish (US)
Pages (from-to)1407-1411
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume85
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Gene Deletion
Body Composition
Insulin-Like Growth Factor I
Insulin Resistance
Genes
Bone
Insulin
Chemical analysis
Bone Density
Minerals
Therapeutics
Reference Values
Bone and Bones
Physiologic Calcification
Glucose
Growth
Bone Remodeling
Bone Development
Osteocalcin
Alkaline Phosphatase

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. / Woods, Kathryn (Katie); Camacho-Hübner, C.; Bergman, R. N.; Barter, D.; Clark, A. J L; Savage, M. O.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 85, No. 4, 2000, p. 1407-1411.

Research output: Contribution to journalArticle

Woods, Kathryn (Katie) ; Camacho-Hübner, C. ; Bergman, R. N. ; Barter, D. ; Clark, A. J L ; Savage, M. O. / Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. In: Journal of Clinical Endocrinology and Metabolism. 2000 ; Vol. 85, No. 4. pp. 1407-1411.
@article{58da2f39031c495d8ec95380dba45b87,
title = "Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion",
abstract = "We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature. Recombinant human IGF-I (rhIGF-I) therapy has been shown to improve insulin sensitivity (Si) and growth in other causes of IGF-I deficiency. We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient, rhIGF-I therapy was initiated at age 16.07 yr (bone age, 14.2 yr), at a starting dose of 40 μg/kg daily, increasing after 3 months to 80 μg/kg daily. Body composition, BMD, markers of bone mineralization, and auxological parameters (height, weight) were measured at 0, 6, and 12 months after start of therapy. Si, acute insulin response to glucose, and glucose effectiveness were determined at baseline, 3 months, and 12 months into therapy. On IGF-I therapy, body mass index increased from 17 kg/m2 to 18.6 kg/m2. Body composition studies (dual-energy x-ray absorbtiometry) revealed an initial decrease in total body fat, from 19.9{\%} at baseline to 15.1{\%} at 6 months; but by 12 months of therapy, this had reversed, with an increase to 21.8{\%}. Si, calculated using Bergman's minimal model, was substantially reduced at baseline at 1.45 × 10-4 min-1 (μU/mL) [normal value, 5.1 × 10-4 min-1 (lean adult male)], rhIGF-I therapy resulted in a dose related improvement of Si into the normal range (NR) (rhIGF-I dose: 40 μg/kg·day, Si = 2.06 × 10-4 min-1; rhIGF-I dose: 80 μg/kg·day, Si = 4.39 × 10-4 min-1). Baseline reduction in Si was accompanied by elevated acute insulin response to glucose, which also fell in a dose-dependent manner. Baseline BMD was severely reduced when compared with age-matched controls (-4.88 SD); however, calculation of bone mineral apparent density indicated that the true reduction in BMD was minimal, rhIGF-I therapy increased BMD by 17{\%} and bone mineral apparent density by 7{\%}, indicating that IGF-I has a greater effect on bone growth than bone mineralization. Bone turnover markers also increased on rhIGF-I; mean serum osteocalcin: 8.3 ng/mL pretreatment, 21.7 ng/mL after 6 months of rhIGF-I (NR for adult male, 3.4-9.1 ng/mL); mean bone specific alkaline phosphatase: 36.5 U/L pretreatment, 82.2 U/L after 6 months of therapy (NR for adult male, 15-41). Height velocity increased from 3.8 cm/yr pretreatment to 7.3 cm/yr on 80 μg/kg·day of rhIGF-I. In this patient with severe insulin resistance, therapy with rhIGF-I resulted in beneficial effects on Si, body composition, bone size, and linear growth. These results have implications for IGF-I therapy in a variety insulin resistant states.",
author = "Woods, {Kathryn (Katie)} and C. Camacho-H{\"u}bner and Bergman, {R. N.} and D. Barter and Clark, {A. J L} and Savage, {M. O.}",
year = "2000",
doi = "10.1210/jc.85.4.1407",
language = "English (US)",
volume = "85",
pages = "1407--1411",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion

AU - Woods, Kathryn (Katie)

AU - Camacho-Hübner, C.

AU - Bergman, R. N.

AU - Barter, D.

AU - Clark, A. J L

AU - Savage, M. O.

PY - 2000

Y1 - 2000

N2 - We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature. Recombinant human IGF-I (rhIGF-I) therapy has been shown to improve insulin sensitivity (Si) and growth in other causes of IGF-I deficiency. We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient, rhIGF-I therapy was initiated at age 16.07 yr (bone age, 14.2 yr), at a starting dose of 40 μg/kg daily, increasing after 3 months to 80 μg/kg daily. Body composition, BMD, markers of bone mineralization, and auxological parameters (height, weight) were measured at 0, 6, and 12 months after start of therapy. Si, acute insulin response to glucose, and glucose effectiveness were determined at baseline, 3 months, and 12 months into therapy. On IGF-I therapy, body mass index increased from 17 kg/m2 to 18.6 kg/m2. Body composition studies (dual-energy x-ray absorbtiometry) revealed an initial decrease in total body fat, from 19.9% at baseline to 15.1% at 6 months; but by 12 months of therapy, this had reversed, with an increase to 21.8%. Si, calculated using Bergman's minimal model, was substantially reduced at baseline at 1.45 × 10-4 min-1 (μU/mL) [normal value, 5.1 × 10-4 min-1 (lean adult male)], rhIGF-I therapy resulted in a dose related improvement of Si into the normal range (NR) (rhIGF-I dose: 40 μg/kg·day, Si = 2.06 × 10-4 min-1; rhIGF-I dose: 80 μg/kg·day, Si = 4.39 × 10-4 min-1). Baseline reduction in Si was accompanied by elevated acute insulin response to glucose, which also fell in a dose-dependent manner. Baseline BMD was severely reduced when compared with age-matched controls (-4.88 SD); however, calculation of bone mineral apparent density indicated that the true reduction in BMD was minimal, rhIGF-I therapy increased BMD by 17% and bone mineral apparent density by 7%, indicating that IGF-I has a greater effect on bone growth than bone mineralization. Bone turnover markers also increased on rhIGF-I; mean serum osteocalcin: 8.3 ng/mL pretreatment, 21.7 ng/mL after 6 months of rhIGF-I (NR for adult male, 3.4-9.1 ng/mL); mean bone specific alkaline phosphatase: 36.5 U/L pretreatment, 82.2 U/L after 6 months of therapy (NR for adult male, 15-41). Height velocity increased from 3.8 cm/yr pretreatment to 7.3 cm/yr on 80 μg/kg·day of rhIGF-I. In this patient with severe insulin resistance, therapy with rhIGF-I resulted in beneficial effects on Si, body composition, bone size, and linear growth. These results have implications for IGF-I therapy in a variety insulin resistant states.

AB - We have recently reported a patient with a homozygous partial deletion of the insulin-like growth factor-I (IGF-I) gene, resulting in IGF-I deficiency, insulin resistance, and short stature. Recombinant human IGF-I (rhIGF-I) therapy has been shown to improve insulin sensitivity (Si) and growth in other causes of IGF-I deficiency. We now report results of 1 yr of rhIGF-I therapy on body composition, bone mineral density (BMD), insulin sensitivity, and linear growth in this patient, rhIGF-I therapy was initiated at age 16.07 yr (bone age, 14.2 yr), at a starting dose of 40 μg/kg daily, increasing after 3 months to 80 μg/kg daily. Body composition, BMD, markers of bone mineralization, and auxological parameters (height, weight) were measured at 0, 6, and 12 months after start of therapy. Si, acute insulin response to glucose, and glucose effectiveness were determined at baseline, 3 months, and 12 months into therapy. On IGF-I therapy, body mass index increased from 17 kg/m2 to 18.6 kg/m2. Body composition studies (dual-energy x-ray absorbtiometry) revealed an initial decrease in total body fat, from 19.9% at baseline to 15.1% at 6 months; but by 12 months of therapy, this had reversed, with an increase to 21.8%. Si, calculated using Bergman's minimal model, was substantially reduced at baseline at 1.45 × 10-4 min-1 (μU/mL) [normal value, 5.1 × 10-4 min-1 (lean adult male)], rhIGF-I therapy resulted in a dose related improvement of Si into the normal range (NR) (rhIGF-I dose: 40 μg/kg·day, Si = 2.06 × 10-4 min-1; rhIGF-I dose: 80 μg/kg·day, Si = 4.39 × 10-4 min-1). Baseline reduction in Si was accompanied by elevated acute insulin response to glucose, which also fell in a dose-dependent manner. Baseline BMD was severely reduced when compared with age-matched controls (-4.88 SD); however, calculation of bone mineral apparent density indicated that the true reduction in BMD was minimal, rhIGF-I therapy increased BMD by 17% and bone mineral apparent density by 7%, indicating that IGF-I has a greater effect on bone growth than bone mineralization. Bone turnover markers also increased on rhIGF-I; mean serum osteocalcin: 8.3 ng/mL pretreatment, 21.7 ng/mL after 6 months of rhIGF-I (NR for adult male, 3.4-9.1 ng/mL); mean bone specific alkaline phosphatase: 36.5 U/L pretreatment, 82.2 U/L after 6 months of therapy (NR for adult male, 15-41). Height velocity increased from 3.8 cm/yr pretreatment to 7.3 cm/yr on 80 μg/kg·day of rhIGF-I. In this patient with severe insulin resistance, therapy with rhIGF-I resulted in beneficial effects on Si, body composition, bone size, and linear growth. These results have implications for IGF-I therapy in a variety insulin resistant states.

UR - http://www.scopus.com/inward/record.url?scp=0034458337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034458337&partnerID=8YFLogxK

U2 - 10.1210/jc.85.4.1407

DO - 10.1210/jc.85.4.1407

M3 - Article

C2 - 10770174

AN - SCOPUS:0034458337

VL - 85

SP - 1407

EP - 1411

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -